References
- Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30:820–829.
- Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia. 2008;22:1841–1848.
- Ingram W, Lea NC, Cervera J, et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia. 2006;20:1319–1321.
- Musto P, Simeon V, Guariglia R, et al. Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy. Onco Targets Ther. 2014;7:1043–1050.
- Azaceta G, Calasanz MJ, Dourdil V, et al. Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation. Leuk Lymphoma. 2010;51:1941–1943.
- Wong KF, Wong WS, Siu LL, et al. JAK2 V617F mutation is associated with 5q-syndrome in Chinese. Leuk Lymphoma. 2009;50:1333–1335.
- Saft L, Karimi M, Ghaderi M, et al. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica. 2014;99:1041–1049.
- Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
- Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
- Giagounidis AA, Germing U, Haase S, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia. 2004;18:113–119.
- Gohring G, Giagounidis A, Aul C, et al. Long-term cytogenetic follow-up of MDS patients with 5q-treated with in the MDS-003 study (CC-5013-MDS-003): evolution to complex clones and progression to AML. Blood. 2008;112:Abstract 1647.
- Lazarevic VLJ, Tomin D, Jankovic GM, et al. A novel t(2;17) in transformation of essential thrombocythemia to acute myelocytic leukemia. Cancer Genet Cytogenet. 2004;148:77–79.
- Van den Berghe H, Vermaelen K, Mecucci C, et al. The 5q-anomaly. Cancer Genet Cytogenet. 1985;17:189–255.
- Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943–2964.